Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release – ‘Wockhardt’s Fifth Novel Antibiotic, Foviscu® (WCK 4282), Matches Gold-Standard Meropenem in pivotal Phase 3 Trial as First-Line Therapies Fail Against Rising Resistance’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.
The above information is a part of company’s filings submitted to BSE.